Results 141 to 150 of about 3,132 (216)

Faricimab for treatment-naïve nAMD: 1- and 2-year outcomes and PS-OCT polarimetric entropy. [PDF]

Int Ophthalmol
Katabami T, Ota M, Saeki Y, Yashiro K, Aoki S, Kitamoto K, Terao R, Azuma K.   +7 more
europepmc   +1 more source

Faricimab for Diabetic Macular Edema in Eyes Vitrectomized for Proliferative Diabetic Retinopathy: A 12-Month Retrospective Study. [PDF]

J Clin Med
Yoon K, Usui-Ouchi A, Sakanishi Y, Ebihara N, Nakao S.   +4 more
europepmc   +1 more source

Letter to the Editor Regarding "Aflibercept 8 mg versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials". [PDF]

Ophthalmol Ther
Panos GD.
europepmc   +1 more source

Advances in Polypoidal Choroidal Vasculopathy (PCV) Management: Emerging Evidence for Faricimab and Aflibercept 8 mg. [PDF]

Ophthalmol Ther
Sherif MZ, Teo KYC, Lai TYY, Chan HH, Fenner BJ, Lee WK, Cheung CMG.   +6 more
europepmc   +1 more source

Baseline Biomarkers Associated with Early Anatomical Response After Faricimab Loading Therapy in Treatment-Naïve Neovascular Age-Related Macular Degeneration. [PDF]

Biomedicines
Ikeuchi E, Miki A, Oka T, Kishimoto-Kishi M, Nakamura M.   +4 more
europepmc   +1 more source

Real-World Outcomes of Faricimab for Polypoidal Choroidal Vasculopathy in a Multi-ethnic Cohort: A 12-Month Retrospective Study. [PDF]

Ophthalmol Ther
Fu DJ, Riotto E, Nicholson L, Fasolo S, Trivizki O, Spooner K, Sivaprasad S, Faes L.   +7 more
europepmc   +1 more source

Dynamics of Hyper-Reflective Foci and Hard Exudates in Diabetic Macular Edema Treated with Faricimab. [PDF]

J Clin Med
Widmann-Sedlnitzky P, Huber KL, Steiner I, Gumpinger M, Stino H, Schmoll T, Schmidt-Erfurth U, Sacu S, Pollreisz A.   +8 more
europepmc   +1 more source

Six-Month Real-World Data in Macular Edema Due to Retinal Vein Occlusion Treated with Faricimab: Swiss Retina Research Network Report. [PDF]

Ophthalmol Ther
Heck K, Hatz K, Cattaneo M, Pfister I, Magnin S, Ruscitti L, Stasik I, Tillmann A, Shamshiev M, Fang J, Weinberger A, Zweifel SA, Garweg JG, Eandi CM, Grimaldi G, Munk MR, Somfai GM, Ambresin A, Feltgen N.   +18 more
europepmc   +1 more source

A Response to: Letter to the Editor Regarding "Aflibercept 8 mg Versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials". [PDF]

Ophthalmol Ther
Friedman SM, Xu Y, Sherman S, Kuznik A, Mojebi A, Keeping S, Chan K, Leng T, Patel N.   +8 more
europepmc   +1 more source

Real-World Functional and Anatomical Outcomes of Intravitreal Faricimab in Suboptimal Responders With Neovascular Age-Related Macular Degeneration: A 24-Month Clinical Audit. [PDF]

Cureus
Sukumaran D, Benjamin D, Abdul Karim MN, Amankwah R, Maharajan P, Mubashar M, Sarmad A, Sharma P, Dhar-Munshi S.   +8 more
europepmc   +1 more source